News
ICER says AZ's new hypertension drug too expensive
ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.
News
Another 340B lawsuit gets underway, in Illinois
Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.
News
Manufacturing issues mar ITM's radiopharma filing, says FDA
ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.
News
Trump order upturns federal childhood vaccines policy
Trump has signed an order that rips up the current US policy on childhood vaccines, demanding changes that experts say will put children at risk.
News
UK is first European country to approve Lilly's Foundayo
Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
